HC Wainwright restated their buy rating on shares of Nuvectis Pharma (NASDAQ:NVCT – Free Report) in a research note published on Friday morning, Benzinga reports. They currently have a $21.00 price objective on the stock.
Nuvectis Pharma Price Performance
NASDAQ:NVCT opened at $14.50 on Friday. Nuvectis Pharma has a 1 year low of $6.21 and a 1 year high of $18.65. The stock’s 50 day simple moving average is $14.50 and its two-hundred day simple moving average is $14.80. The company has a market cap of $249.85 million, a price-to-earnings ratio of -9.35 and a beta of 0.09.
In related news, major shareholder Marlio Charles Mosseri bought 6,091 shares of the business’s stock in a transaction dated Wednesday, June 21st. The shares were purchased at an average price of $17.71 per share, with a total value of $107,871.61. Following the transaction, the insider now owns 2,431,091 shares in the company, valued at approximately $43,054,621.61. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last 90 days, insiders have purchased 146,817 shares of company stock valued at $2,410,305. 38.85% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Nuvectis Pharma
About Nuvectis Pharma
Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate that inhibits the Proto-oncogene c-Src and YES1 kinases.
- Five stocks we like better than Nuvectis Pharma
- Are Penny Stocks a Good Fit for Your Portfolio?
- 2 Recession-Proof Intelligence Stocks to Defend Your Portfolio
- How to Invest in Growth Stocks
- 5 Reasons Mullen Automotive is About to Turn a Corner
- Energy and Oil Stocks Explained
- Qualcomm and Apple Forge Ahead with New Modem Partnership
Receive News & Ratings for Nuvectis Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectis Pharma and related companies with MarketBeat.com's FREE daily email newsletter.